What is Pmv Pharmaceuticals?
Headquartered in Princeton, New Jersey, Pmv Pharmaceuticals is a clinical-stage precision oncology firm dedicated to the development of small molecule therapies. The company's core innovation lies in its ability to structurally correct the geometry of mutant p53 proteins, a critical tumor suppressor gene frequently altered in human cancers. By restoring the function of these proteins, Pmv Pharmaceuticals aims to deliver tumor-agnostic treatments that provide therapeutic benefits across a diverse spectrum of cancer types. Since its 2020 public listing on the NASDAQ, the company has maintained a focus on selective targeting of gene mutations, positioning itself as a leader in the next generation of precision medicine.
How much funding has Pmv Pharmaceuticals raised?
Pmv Pharmaceuticals has raised a total of $498M across 5 funding rounds:
Series A
$30M
Series B
$74M
Series C
$62M
Series D
$70M
Stock Offering
$212M
Series A (2014): $30M with participation from InterWest Partners, OrbiMed, and Osage University Partners
Series B (2017): $74M led by Topspin Biotech Fund, InterWest Partners, Osage University Partners, and OrbiMed
Series C (2019): $62M, investors not publicly disclosed
Series D (2020): $70M featuring Avoro Capital Advisors LLC, Viking Global Investors, Boxer Capital , LLC, OrbiMed Advisors LLC, Wellington Management Company LLP., RA Capital Management LP, and Nextech Invest Ltd
Stock Issuance/Offering (2020): $212M, investors not publicly disclosed
Key Investors in Pmv Pharmaceuticals
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm focused on the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms to support innovation at various development stages.
Viking Global Investors
Viking Global Investors is a global investment firm specializing in research-intensive, long-term focused investments using fundamental analysis to select public and private equity interests across industries.
Wellington Management Company LLP.
Wellington Management Company, LLP is a global, independent investment management firm providing institutional clients with portfolio management, research, and tailored investment solutions across diverse asset classes.
What's next for Pmv Pharmaceuticals?
With the support of its recent capital influx, Pmv Pharmaceuticals is well-positioned to advance its pipeline of small molecule candidates through critical clinical milestones. The company's strategic roadmap emphasizes the expansion of its tumor-agnostic platform, leveraging its unique structural biology expertise to address previously undruggable targets. As the firm continues to scale, the focus will likely shift toward optimizing clinical trial designs and exploring potential collaborative partnerships to broaden the reach of its therapeutic candidates. The ongoing commitment from institutional backers suggests a long-term outlook focused on sustainable growth and the delivery of transformative oncology solutions to patients globally.
See full Pmv Pharmaceuticals company page
